Результаты операции ТМЛР в сочетании с введением ангионенных факторов у больных ИБС с поражением дистального русла

Список литературы

1. Беришвили И.И. Трансмиокардиальная лазерная реваскуляризация миокарда. Информационный сборник «Сердечно-сосудистая хирургия». Серия Медицина, 2004, 1:15−23
2. Бокерия Л.А., Беришвили И. И., Асланиди И. П., Вахромеева М. Н. Трансмиокардиальная лазерная реваскуляризация перфузия, функция и метаболизм. Издательство НЦ ССХ им. А. Н. Бакулева. Москва. 2004.
3. Бокерия Л.А., Голухова Е. З., Еремеева М. В. и др. Первый опыт клинического применения терапевтического ангиогенеза с использованием гена VEGF165 человека. Бюллетень НЦ ССХ им. А. Н. Бакулева РАМН, 2004, том5 № 4: с. 134−142.
4. Бокерия Л.А., Гудкова Р. Г. Сердечно-сосудистая хирургия -2000. Анналы хирургии, 2001, 6:5−33.
5. Вахромеева М.Н. «Отбор больных и оценка результатов трансмиокардиальной лазерной реваскуляризации с помощью методов ядерной медицины». Москва, 2004. Докт. дисс.
6. Вахромеева М.Н. Отбор больных и оценка результатов трансмиокардиальнои лазерной реваскуляризации с помощью методов ядерной медицины. Дисс. докт., М, 2003.
7. Демидова О.А. «Комбинированное лечение хронической ишемии нижних конечностей с использованием стимуляторов ангиогенеза» Москва, 2005. Канд. дисс.
8. Лукашкин М.А. «Экспериментальное обоснование и оценка первого опыта клинического применения терапевтического ангиогенеза с использованием генов VEGF и bFGF». Москва, 2005. Канд. дисс.
9. Старостин М.В. Непосредственные результаты сочетанных операций трансмиокардиальнои лазерной реваскуляризации и аортокоронарного шунтирования у больных ИБС. Дис. Канд. М. 2003.
10. Abramov D., Tamariz M.G., Freme S.E. et al. Trends in coronary artery bypass surgery results: a recent, 9-year study .Ann. Thorac. Surg., 2000,70:84−90
11. Actis-Dato G., Hakimpour M., Bacciega M. et al TMR and CABG: the best way to obtain a complete and more lasting revascularization? Ann. Thorac. Surg., 2000, 69: 1983−1985
12. Allen K.B., Dowling R.D., Angell W.W., et d. Transmyocardial Revascularization 5-year Follw-Up of a Prosepective, randomized multicenter Trial. Ann. Thorac. Surg., 2004, 77,4: 1228−1234
13. Allen K.B., Dowling R.D., DelRossi A J., et al. Transmyocardial laser revascularization combined with coronary artery bypass grafting a multicenter, blinded, prospective, randomized, controlled trial. J. Thorac. Cardiovsac. Surg. 2000−119:540−549
14. Allen KB, Dowling RD, Fudge TL, et al. Comparison of tranmyocardial revascularization with medical therapy inpatients with refractory angina. NEnglJMed 1999- 341: 1029−36.
15. Alon Т., Hemo I., Itin A., et al. Vascular endothelial growth factor acts assurvival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995- 1: 1024−8.
16. Aoki M., Morishita R., Taniyama Y., et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 2000- 7: 417−27.
17. Athanasiou Т., Al-Ruzzeh S., Kumar P., et al. Off-pump Myocardial Revascularization is associated with less incidenceof stroke in Elolerly Patients. Ann.Thorac.Surg., 2004−77:745−753
18. Atluri P., Panlilio C.M., Liao G.P., et al. Transmyocardial revascularization to enhance myocardial vasculogenesis and hemodynamic function. Journal of Thoracic and Cardiovascular Surgery, 2008- vol.135- № 2: 283−290.
19. Auerbach R., Kabail L., Knighton D., Folkman J. A simple procedure for the long-term cultivation of chicken embryo. Dev. Boil., 1974, 41: 391−394
20. Autiero M., Waltenberger J., Communi D., et al. Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Fltl and Flkl. Nat Med 2003−9:936−43.
21. Baffour R, Garb JL, Kaufman J, Berman J, Rhee SW, Norris MA et al. Angiogenic therapy for the chronically ischemic lower limb in a rabbit model. J Surg Res 2000−93:219−29.
22. Banai S, Jaklitsch MT, Casscells W, Shou M, Shrivastav S, Correa R et al. Effects of acidic fibroblast growth factor on normal and ischemic myocardium. CircRes 1991−69:76−85.
23. Banai S., Jakhtsch M.T., Shou M. Angioginic-induced inhancement of collateral blood flow to ischemic myocardium by vascular endothehal growth factor in dogs // Circulation.1994. Vol. 89. P. 2183−2189
24. Banai, S., Shweiki, D., Pinson, A., Chandra, M., Lazarovici, G., and
25. Keshet, E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc. Res. 1994- 28: 1176−1179.
26. Battler A, Scheinowitz M, Bor A, Hasdai D, Vered Z, Di Segni E et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993−22:2001−6.
27. Bauters, C., Asahara, Т., Zheng, L. P., Takeshita, S., Bunting, S., Ferrara, N., et al. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am. J. Physiol. 1994- 267: H1263-H1271.
28. Beranec J. T. Apoptosis in transmyocardial and percutaneous myocardial revascularization. Mayo Clin Proc, 1999, 74, 11 831 184.
29. Bockeria L., Berishvili I. Transmyocardial laser revascularization: 10-year experience. Abstracts 56-th ESCVS Meeting Interact. Cardiovasc. Thorac. Surg. 2007, vol.6 (suppl.l):S53.
30. Bokeria L.A., Golukhova E.Z., Eremeeva M.V.and Berishvili I.I. Gene and Cell Therapy: Alternative Approach for Myocardial Revascularization. 6th International Congress on Coronary Artery Disease, 2005: 383−386.
31. Bortone A.S., D’Agostino D., Schena S. H pp. Inflammatory response and angiogenesis after percutaneous Transmyocardial laser revascularization Ann. Thorac. Surg., 2000, 70: 1134−1136
32. Bridges C. R. Myocardial laser revascularization. The controversy and the data. Ann Thorac Surg, 2000, 69, 655−62
33. Bridges C.R., Horvath K.A., Nugent W.C., Shahian D.M., Haan C.K., Shemin R.J., Allen K.B., Edwards F.H. The Society of Thoracic Surgeons Practice guideline Series: Transmyocardial laser revascularization. Ann. Thorac. Surg., 2004, 77: 14 941 502
34. Burkhoff D., Kornowski R. An examination of potentialmechanisms underlying transmyocardialrevascularizationxhannels, angiogenesis and neuronaleffects.Semin. Intervent. Cardiol.2000,5: 71−74
35. Burkhoff D., Wesley M.N., Resar J.R., Lansing A.M. Factors correlating with risk of mortality after transmyocardial laser revascularization. J. Am. Coll. Cardiol., 1999, 34, 1: 55−61.
36. Burns S.M., Sharpies L.D., Tait S. et al. The transmyocardial laser revascularization international registry report // Eur. Heart
37. J. -1999. -Vol. 20. -No 1. -P. 31−37.
38. Cao G., O’Brien C., Zhou Z., et al. Involvement of human PECAM-1 inangiogenesis and in vitro endothelial cell migration. Am J Physiol Heart Circ Physiol 2002- 282: CI 181−1190.
39. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E et al Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003−9:604−13
40. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000- 6: 389−395.
41. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., et al. Abnormal blood vessel development and lethality inembryos lacking a single VEGF allele. Nature 1996- 380: 435−439.
42. Carmeliet, P., Moons L., Luttun A., et al. Synergism between vascularendothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001−7:575−83.
43. Celletti, F. L., Waugh, J. M., Amabile, P. G., Brendolan, A., Hilfiker, P. R., and Dake, M. D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 2001- 7: 425−429.
44. Chiu VF, Giaid A, Kuang JQ, et al. Thoracic Surgery Directors Association Award Angiogenesis m transmyocardial revascularization comparison of laser versus mechanicalpunctures. Ann Thorac Surg 1999,68: 301−7
45. Chu V, Kuang J, McGinn A, Giaid A, Korkola S, Chiu RC Angiogenic response induced by mechanical transmyocardial revascularization. Thorac Cardiovasc Surg 1999,118:849−56
46. Conway E.M., Collen D., Carmeliet P. Molecular mechanisms ofblond vessal growth.Cardiovasc. Res. 2001,49:509−521
47. Cuevas P, Carceller F, Lozano RM, Crespo A, Zazo M, Gimenez-Gallego
48. G. Protection of rat myocardium by mitogenic and non-mitogenic fibroblast growth factor during post-ischemic reperfusion. Growth Factor 1997- 15−40
49. Cuevas P, Reimers D, Carceller F, Martinez-Coso V, Redondo-Horcajo M, Saenz de Tejada I et al. Fibroblast growth factor-1 prevents myocardial apoptosis triggered by ischemia reperfusion injury. Eur J Med Res, 1997−2:465−8.
50. Darland D., D’Amore P. Blood vessel maturation: vascular development comes of age. J Clin Invest 1999- 103: 157−8.
51. De Muinck E., Simons M. Re-evaluating neovascularization. J Mol Cell Cardiol.2004−36:25−32.
52. De Muinck E., Simons M. Re-evaluating neovascularization. J Mol Cell Cardiol.2004−36:25−32.
53. Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapiere CM. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 1997−57:5590−7.
54. Devlin GP, Fort S, Yu E, Cusimano RJ, Wei K, Rakowski H et al. Effect of a single bolus of intracoronary basic fibroblast growth factor on perfusion in an ischemic porcine model. CanJCardiol 1999- 15:676−82.
55. Diegeler A., Schneider J., Lauer В., Mohr F.W., Kluge R. Transmyocardial laser revascularization using the Holmium-YAG laser for treatment of end stage coronary artery desease // Eur. J. Cardiothorac. Surg. 1998. -Vol.13. -P. 392−397.
56. Diendl E., Hoefer I., Fernandez В., et al. Involvement of the fibroblast growth factor systev in adaptive and chemokine-induced arteriogenesis. Circ Res 2003−92:561−568.
57. Domkowski P., Biswas S., Steenbergen C., et al. Histological evidence of angiogenesis 9 months after transmyocardial laser revascularization. Circulation, 2001−103:469−471.
58. Dor, Y., Djonov, V., Abramovitch, R., Itin, A., Pishman, G. I., Carmeliet,
59. P., et al. Conditional switching of VEGF provides new insights into adult neovascularizadon and pro-angiogenic therapy. EMBO J. 2002- 21: 1939−1947.
60. Dzau VJ, Mann MJ, Ehsan A, Gries DP. Gene therapy and genomic strategies for cardiovascular surgery: the emergine field of surgiomics. J Thorac Cardiovasc Surg 2001−121:206−16.
61. Elicieri B. Integrin and growth factor receptor crosstalk. Circ Res 2001- 89: 1104−1110.
62. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K. S., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996- 380: 439−442.
63. Ferrare N, Alitano K, Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999−5:1359−64.
64. FGF-4 gene therapy GENERX—Collateral Therapeutics. BioDrugs 2002- 16.75−6.
65. Fleischer KJ, Goldschmidt-Clermont PJ, Fonger JD, Hutchins GM, Hruban RH, Baumgartner WA One-month histologic response of transmyocardial laser channels with molecular intervention. Ann. Thorac. Surg.1996, vol. N2 4: 1051−1058
66. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J1. Med 1971−285:1182−6.
67. Folkman J., Klagsbrun M. Angiogenic factors. Science, 1987−235: 442−7.
68. Frazier O.H., March R.J., Horvath K.A. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N.Engl. J. Med., 1999, 341: 1021−1028.
69. Frenkel-Denkberg G., Gershon D., Levy A. The function of hypoxia-inducible factor 1 (HIF-1) is impraired in senescent mice. FEBS Lett 1999- 462: 341−4.
70. Fuchs S, Vodovotz Y, Leon MB, Kornovski R. Laser myocardial revascularization enhances expression of angiogenic cytokines in a porcine model of chronic ischemia. J Thorac Coll Cardiol, 1999−33:342A
71. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R ef al. Inhibition of ubiquitin-proteasome pathway-ediated I kappa В alpha degradation by a naturaly occurring antibacterial peptide. J Clin Invest 2000- 106:439−48.
72. Gao, Y., Lecker, S., Post, M. J., Hietaranta, A. J., Li, J., Volk, R., et al. Inhibition of ubiquitin-proteasome pathway-mediated I kappa В alpha degradation by a naturally occurring antibacterial peptide. J. Clin. Invest. 2000- 106: 439−448.
73. Gassier N, Wintzer HO, Stubbe HM, Wullbrand A, Helm-chen U. Transmyocardial laser revascularization histologi-cal features in human nonresponder myocardium Circulation 1997,95:371−5
74. Gaudino M., Glieca F., Alessandrini F. et al. High Risk Coronary Artery Bypass Patient: incidence, surgical strategiesand Results.Ann. Thorac. Surg., 2004,77:574−580
75. Geist A., Marx J., Muller S., Lezen A., von Specht B.U., Haberstroch J,
76. Combination of enoxeparin and Fibroblast growth factor-1 in creases myocardial blood flogs and Capillary density after myocardial Infarction in Rebbits. Eur. Surg. Research. 2005, 37- 191−198
77. Gille, J., Khalik, M., Konig, V., and Kaufmann, R. Hepatocyte growthfactor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. J. Invest Dermato. 1998- 111:1160−1165.
78. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996−2:534−9.
79. Gospodarowicz D, Cheng J, Lui GM, Baird A, Esch F, Bohlen P. Corpus luteum angiogenic factor is related to fibroblast growth factor. Endocrinology 1985−117:2383−91
80. Gospoderowitz D., Cheng J. Heparin protects basic and seidic FGF from inactivation J. Cell Physiol. 1986, 128: 475- 484
81. Grines, C. L., Watkins, M. W., Helmer, G., Penny, W., Brinker, J., Marmur, J. D., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002- 105: 1291−1297.
82. Guleserian KJ, Maniar HS, Camillo CJ, Bailey MS, Damino Rj Jr, Moon MR. Quality of life and survival aftertransmyocardial laser revascularization with the holmium: YAG laser. Ann Thorac Surg. 2003 Jun-75(6):1842−7-discussion 1847−8.
83. Hamaway A., Lee L., Crystal R., et al. Cardiac angiogenesis and gene therapy: a strategy for myocardial revascularization. Curr Opin Cardiol 1999- 14: 515−22.
84. Hammond, H. K. and McKiman, M. D. Angiogenic gene therapy for heart disease: A review of animal studies and clinical trials. Cardiovasc. Res. 2001- 49: 561−567.
85. Harada, K., Grossman, W., Friedman, M., Edelman, E. R., Prasad, P. V., Keighley, C. S., et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J. din. Invest. 1994- 94: 623 630.
86. Hata Y, Rook SL, Aiello LP. Basic fibroblast growth factory induces expression of VEGF receptor KDR through a protein kinase С and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes 1999−48:1145−55.
87. Hattori K., Heissig В., Wu Y., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002−8:841−9.
88. Hellstrom, M., Gerhardt, H., Kalen, M., Li, X., Eriksson, U., Wolburg, H., et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol 2001- 153: 543−553.
89. Helmlinger G., Endo M., Ferrara N., et al. Formation of endothelial cell networks. Nature 2000−405:139−41.
90. Henry TD, Abraham JA. Review of preclinical and clinical results with vascular endothelial endothelial growth factors for therapeutic angiogenesis. Curr Intervent Cardiol Rep 2000−2-228−41.
91. Henry, Т., Annex, В., Azrin, M., McKendall, G., Willerson, J., Hendel, R., et al. Final results of the VIVA trial of rhVEGF human therapeutic angiogenesis. Circulation 1999- 100: 1−476.
92. Henry, Т., Annex, В., Azrin, M., McKendall, G., Willerson, J., Hendel, R., et al. Final results of the VIVA trial of rhVEGF human therapeutic angiogenesis. Circulation 2003- 107: 1359−1365.
93. Hood J., Bednarski M., Frausto R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002−296:2404−7.
94. Horowitz A, Simons M. Regulation of syndecan-4 phosphorylation in vivo. J Biol Chem 1998−273:10 914−8.
95. Horowitz A., Tkachenko E., Simons M., et al. Fibroblast growth factor-specific modulation of cellular response by syndecan-4. J Cell Biol 2002−157:715−25.
96. Horvath K., Transmyocardial laser revascularization. Chapter 15 in Advanced Therapy in Cardiac Surgery ed by K.L.Franco, E.D.Verrier. ВС Decker inc., Hamilton, London, 2003, pp.131−137.
97. Horvath KA, Chiu E, Maun DC, et al Up-regulation of VEGF mRNA and angiogenesis after transmyocardial laser revas cularization Ann Thorac Surg 1999,68: 825−9
98. Horvath KA, Cohn LC, Cooley DA, et al Transmyocardial laser revascularization results of multi-center trial using TLR as soletherapy for end stage coronary artery disease J Thorac
99. Cardiovasc Surg 1997,113: 645−54
100. Huang Z, Chen K, Huang PL, Finklestein SP, Moskowitz MA. bFGFameliorates focal ischemic injury by blood flow-independent mechanisms in eNOS mutant mice. Am J Physiol 1997−272:H1401−5.
101. Hughes G.C., Kypson A.P., Louis J.D. et al. Induction of angiogenesis after TMR: a comparison of holmium: YAG, C02and eximer laser. Ann.Thorac. Surg., 2000−70:504−509
102. Hughes GC, Biswas SS, Yin B, Coleman RE et al. Therapeuthic
103. Angiogenesis in Chronically Ischemic Porcine Myocardium: Comparative Effects of bFGF and VEGF. Ann Thorac Surg 2004−77:812−8.
104. Hughes GC, Kypson AP, St. Luis JD, Annex BN, Yin B, Biswas SS, Coleman RE, de Grado TR, Donovan CL, Landolfo KP, Lowe JE. Induction of angiogenesis after TMR: a comparision of holmium: YAG, C02, and eximer laser. Ann Thorac Surg 2000−70:504−509.
105. Isner J. Angiogenesis for revascularization of ischaemic tissues. Eur Heart J 1997- 18: 1−2.
106. Jackson D. The unfolding tale of PECAM-1. FEBS Lett 2003−540: 7−14.
107. Jeevanandam V, Auten JS, Oz MC, Watkins J, Rose EA, Smith CR Myocardial revascularization by laser induced channels1. Surg Forum 1990,41: 225−7
108. Jiang ZS, Padua RR, Ju H, Doble ВW, Jin Y, HaoJ etal. Acute protection ofischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 2002−282.-H1071−80.
109. Johnston G. Goss J.R., Malmgren J.A., Spertus J.A. Healf status and social risr correlates of extended lenght of Stay follou wing coronari artery bypass surgery. Ann Thorac Surg 2004,77:557 562
110. Kantor B., McKenna C.J., Caccitolo J.A. et al. Transmyocardial and Percutaneous Myocardial Revascularization: Current and
111. Futur Role in the Treament of Coronary Artery Disease. Mayo1. ClinProc. 1999−74:585−592
112. Kasahara H, Tanaka E, Fukuyama N, Sato E, Sakamoto H, Tabata Y et al.
113. Biodegradable gelatin hydrogel potentiates the angiogenic effect of fibroblast growth factor 4 plasmid in rabbit hindlimb ischemia. J Am Coll Cardiol 2003 -41: 1056−62.
114. Kawasuji M., Nagamine., Ikeda M. et al. Therapeutic angiogenesis with intramyocardial administration of basic fibroblast growth factor. Ann. Thorac. Surg., 2000, 69: 1155−1161.
115. Khurana R, Simons M. Insights from Angiogenesis Trials Using Fibroblast Growth Factor for Advanced Arteriosclerotic Disease. Trends Cardiovasc Med 2003- 13:116−122.
116. Kleiman N.S., Niral C, Keith B.A., sSmons M, et al. Evoling Revascularization Approaches for Myocardial Ischemia. Am J.
117. Cardiol 2003−92(suppl):9N-17N
118. Klein S., Roghani M., Riftin D.B. Fibroblast growth Faktors asangiogenesis factors: a new insight into their mechanism of action Exs., 1997,79: 159−192.
119. Koerselman J., Van der Graaf Y., de Jaegere P.P. Th., Groblee D.E.Coronary Collaterals. An. Important and Underexposed. Aspect of Coronary Artery Disease. Circulation, 2003,107:2507−2511
120. Kohmoto T, DeRosa CM, Yamamoto N, et al Evidence of vascular growth associated with laser treatment of normalcanine myocardium Ann Thorac Surg 1998,65: 1360−7
121. Kojima Т., Takagi A., Maeda M., et al. Plasma levels of syndecan-4ryudocan) are elevated in patients with acute myocardial infarction. Thromb Haemost 2001- 85: 793−799.
122. Kornowski, R., Fuchs, S., Leon, M. В., and Epstein, S. E. Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation 2000- 101:454−458.
123. Kraatz EG, Misfeld M, Jungbluth B, Sievers HH Survival after transmyocardial laser revascularization inrelation to nonlaseredperfused myocardial zones Ann Thorac Surg 2001,71: 532−6
124. Krabatsch T, Schaper F. Leder C, Tulsner J, Thallman U, Hetzer R,
125. Histological findings after transmyocardial laser revascularization. J Card Surg 1996
126. Laham RJ, Rezaee M, Post M, Novicki D, Sellke FW, Pearlman JD et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther 2000−292:795−802.
127. Laham, R. J., Rezaee, M., Post, M., Selike, F. W., Braeckman, R. A., Hung, D., et al. Intracoronary and intravenous administration of basic fibroblast growth factor: Myocardial and tissue distribution. Drug Metab. Dispos. 1999- 27: 821−826.
128. Lansing A. M. Transmyocardial laser revascularization. Ann
129. Thorac Surg, 2000, 70, 1763−64.
130. Lansing A.M. Transmyocardial laser revascularization. Ann Thorac Surg.2000−70:1763.
131. Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995−91.145−53.
132. Lederman R., et al. Therapeutic angiogenesis with recombinant fibroblast growth 2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 2002- 359: 2053−2058.
133. Lee LY, O’Hara MF, Finin EB, et al Transmyocardial laser revascularization with excimer laser: clinical results at 1 vear
134. Ann Thorac Surg 2000,70: 498−503
135. Lee LY, Patel SR, Hackett NR, Mack CA, Poke DR, El-Sawy T et al Focalangiogen therapy using intramyo-cardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000−69:14−23- discussion 23−4.
136. Lee S., Wolf P., Escudero R., et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. New Engl J Med 2000- 342: 626−33.
137. Li J., Partovian C., Hampton Т., et al. Modulation of microvascular signaling by heparin sulfate matrix: studies in syndecan-4 transgenic mice. Microvasc Res 2002−64:38−46.
138. Li L., Couse Т., Deleon H., et al. Regulation of syndecan-4 expression with mechanical stress during the development of angioplasty-induced intimal thickening. J Vase Surg 2002−36:361−70.
139. Li, L., Post, M., Volk, R., Gao, Y., Li, M., Metais, C., et al. PR39, a peptide regulator of angiogenesis. Nat. Med. 2000- 6:49−55.
140. Lopez JJ, Edelman ER, Stamler A, Hibberd MG, Prasad P, Thomas KA etal. Angiogenic potential of perivascu-larly delivered aFGF in a porcine model of chronic myocardial ischemia. Am J Physiol 1998−274:H930−6.
141. Losordo D., Vale P., Isner J. Gene therapy for myocardial angiogenesis. Am Heart J. 1999- 138: S132−41.
142. Loubani M., Chin D., Lewrment J.N., Galinanes M. Mid-term results of combined transmyocardial laser revascularization and coronary artery bypass Ann. Thorac. Surg. 2003, 76: 1163−1166
143. Luo Z, Diaco M, Murohara T, Ferrara N, Isner JM, Symes JF. Vascular Endothelial Growth Factor Attenuates Myocardial Ischemia-Reperfusion Injury. Ann Thorac Surg 1997−64:993−8
144. Lutter G, Martin J, von Samson P, Heilmann C, Sarai K, Beyersdorf F. Microperfusion enhancement after TMLR in chronically ischemic porcine hearts. Cardiovasc Surg 2001−9:281−291.
145. Lutter G, Schwarzkopf J, Lutz C, Martin J, Beyersdorf F. Histologic findings of transmyocardial laser channels after 2 h. Ann Thorac Surg 1998−65:1437−1439.
146. Lutter G., Dern P., atman T. et alCombined use of TMLR with VEGE-CDNA in a model of chronic myocardial ischemia. Jn. :14-th Annual
147. Meeting of the E ACTS: AbstractsFrankfurt. 2000, p.430(N-pl67)
148. Luttun A., Tjwa M., Moons L., et al. Revascularization of ischemic tissuesby PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Fltl. Nat Med 2002−8: 831−40.
149. Mack C.A., Patel S.R., Rosengart Т.К. Myocardial angiogenesis as a possible mechanism for TMLR efficacy. J. Clin Laser Med Surg 1997−15:275−9
150. Malekan R, Reynolds C, Kelley ST, Suzuki Y, Bridges CR Angiogenesis in transmyocardial laser revascularization a non-specific response to injury Circulation 1998,98(Suppl 2): II 62−5
151. March R.J. Transmyocardial laser revascularization with the C02 laser: one year results of a randomized, controlled trial. Semin. Thorac. Cardiovasc. Surg., 1999, 11: 12−18.(110)
152. March R.J., Aranki S., Boyce S., Cohn L.H., Cooley D.A., Crew J.R., Fontana G., Frazier O.H., Griffith B.P., Landolfo
153. Masseri A., Aranjo L., Finocchiaro M. Collateral circulation: heart, brain, kidney, limbs. In: Schaper W., Schaper J., editors. Collateral development and function in man. Boston, VA: Kluwer Academic Publ. 1993, p.381−402.
154. Milano A, Pratali S, Tartarmi G, Mariotti R, De Carlo M, Paterni G, Bom G, Bortolotti U Early results of transmy ocardial revascularization with a holmium laser Ann Thorac Surg 1998,65,(3): 700−704.
155. Mirhoseini M Shelgikar S, Cayton MM New concepts in revascularization of the myocardium. Ann Thorac Surg 1988,45:415−20
156. Mohrman D.E., Feigl E.O. Competition between sympathetic vasoconstriction and metabolic vasodilation in the eaninecoronary circulation. Circ.Res. 1978,42:79−86
157. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblastgrowth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A 1986−83:7297−301.
158. Mueller ХМ, Tevaearai HT, Genton CY, Chaubert P, von Segesser LK, Are there vascular density gradients along myocardial laser channels? Ann Thorac Surg 1999−68:125−130.
159. Mueller XM, Tevaearai HT, Genton CY, Chaubert P, von Segesser LK, Are there vascular density gradients along myocardial laser channels? Ann Thorac Surg 1999−68:125−130.
160. Muhkerjee D., Bhatt D., Roe Т., et al. Direct myocardial revascularization and angiogenesis-how many patients might bealigible? Am J. Cardiol 1999−84:598−600
161. Murakami M., Horowitz A., Tang S., et al. Protein kinase С (PKC) deltaregulates PKCalpha activity in a Syndecan-4-dependent manner. J Biol Chem 2002- 277: 20 367−71.
162. Ortega S, Schaeffer MT, Soderman D, DiSalvo J, Linemeyer DL, Gimenez-Gallego G etal. Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth fac-tor. J Biol Chem 1991−266:5842−6.
163. Osswald B.R., Blackston E.H., Tochtermann U., et al. Does the completeness of revascularization affect early survial after coronary artery bypass grafting in elderly patients? Eur, J.Cardiothorac. Surg.2001 -20:120−125
164. Ozaki S., Meyns В., Verbeken E. Et al. Transmyocardial laser revascularization in a sheep model of ischemic cardiomyopathy // In: 13th Annual Meeting of the SATCS. Abstracts.
165. Glasgow, 1999. № 264. — P. 526.
166. Parsons-Wingerter, P., Elliott, К. E., dark, J. I. and Farr, A. G. Pibroblastgrowth factor-2 selectively stimulates angiogenesis of small vessels in arterial tree. Arterioscler. Thromb. Vase. Biol 2000- 20: 1250−1256.
167. Pearlman, J. D., Hibberd, M. G., Chuang, M. L., Harada, K., Lopez, J. J., Gladstone, S. R., et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat. Med. 1995- 1: 1085−1089.
168. Pecher P., Schumacher B. Angiogenesis in ischemic human myocardium: clinical results after 3 years. Ann Thorac Surg 2000- 69: 1414−9.
169. Pelletier M.P., Giaid A., Sivaraman S. et al. Angiogenesis and growth factor expression in model of transmyocardial revascularization. Ann. Thorac. Surg., 1998, 66, 1: 12−8.
170. Peterson ED, Kaul P, Kaczmarck RG, et al. From controlled trials to clinical practice: monitoring transmyocardial revascularization use and outcome. Am Coll Cardiol 2003,42: 1611−6.
171. Piali L., Hammel P., et al. CD31/ PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol 1995- 130:451−60.
172. Post M., Bao J., Sato K., et al. Adenoviral PR-39 improves perfusion and function in a pig model of chronic myocardial ischemia. Circulation 2002- 106: 11−275.
173. Post MJ, Simons M. The rational phase of therapeutic angiogenesis. Minerva Cardioangiol 2003−51:421−32.
174. Post, M. J., Laham, R., Selike, F. W., and Simons, M. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc. Res. 2001- 49: 522−531.
175. Prchal JT. Delivery on demand a new era of gene therapy? New Engl J Med 2003−348:1282−3.
176. Pu, L. Q., Sniderman, A. D., Arekat, Z., Graham, A. M., Brassard, R., and Symes, J. F. Angiogenic growth factor and revascularization of the ischemic limb: Evaluation in a rabbit model. J. Surg. Res. 1993- 54: 575−583.
177. Pu, L. Q., Sniderman, A. D., Brassard, R., Lachapelle, K. J., Graham, A. M., Lisbona, R., et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 1993- 88: 208−215.
178. Puglisi V. Personal communication. 2004.
179. Rajanayagam MA, Shou M, Thirumurti V, Lazarous DF, Quyyumi AA, Goncalves L et al. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. J Am Coll Cardiol 2000−35:519−26.
180. Rak J. Weitz J.J. Heparin and angiogenesis, size maters Arterioseler. Thromb. Vase. 2003, 23- 1954−1955.
181. Risau W., Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995- 11:73−91.
182. Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI, Vajanto I et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arte-riogenesis in a rabbit hindlimb ischemia model. Faseb J 2003- 17:100−2.
183. Roethy W, Fiehn E, Suehiro K, Gu A, Yi G, Shimizu J et al. A growth factor mixture that significantly enhances angiogenesis in vivo. J Pharmacol Exp Ther 2001−299:494−500.
184. Roham R., m Fernandez A., Udagawa Т., et al. Genetic heterogeneity of angiogenesis in mice. FASEB J 2000- 14: 871−6.
185. Rosengart Т., Patel S., Crystal R. Therapeutic angiogenesis: protein and gene therapy delivery strategies. J Cardiovasc Risk 1999- 6: 29−40.
186. Rosengart TK, Budenbender KT, Duenas M, Mack CA, Zhang QX, Isom OW. Therapeutic angiogenesis: a comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin. J Vase Surg 1997−26:302−12.
187. Ruel M., Laham R., Parker J., et al. Long-term effects of surgical angiogenic therapy with FGF-2 protein. J Thorac Cardiovasc Surg 2002- 124: 28−34.
188. Safi J Jr., Gloe Т., Riccioni Т., et al. Gene therapy with angiogenic factors: a new potential approach to the treatment of ischemic disease. J Mol Cell Cardiol 1997- 29: 2311−25.
189. Sakakibara Y., Tambara K., Sakaguchi G., et al. Toward surgical angiogenesis using slow-released basic fibroblast growth factor. Eur J Cardio Thorac Surg. 2003−24- 105−112.
190. Sato K, Laham RJ, Perlman JD, Novicki D, Sellke FW, Simons M et al. Efficacy of intracoronary intravenous FGF-2 in a pig model of chronic myocardial ischemia. AnnThoracSurg2000−70:2113−8.
191. Sato K, Wu T, Laham RJ, Johnson RB, Douglas P, Li J et al Efficacy of intracoronary or intravenous VEGF 165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 2001−37:616−23.
192. Sauter A., Lambert K., Rupf A., et al. Three-step purification method of large quantities of human recombinant alpha endothelial cellular growth factor for clinical use. Int J Mol Med. 2007- 19(1): 97−103.
193. Sayeed-Shah U, Mann MJ, Martin J, Grachev S, Reimold S, Lourence R et al. Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with trasmyocardial laser revascularization. J Thorac Cardiovasc Surg. 1998- 116:763−9.
194. Schaper W, Sharma HS, Quinkler W, Market T, Wunsch M, Schaper J. Molecular biologic concepts of coronary anastomoses. J Amer Coll Cardiol 1990
195. Schaper W., Ito W. Molecular mechanisms of collateral vessel growth. CircRes 1996- 79:911−9.
196. Schlaudraff K, Schumacher B, von Specht BU, Seitelberger R, Schlosser V, Fasol R. Growth of «new» coronary vascular structures by angiogenetic growth factors. Eur J Cardiothorac Surgl993−7:637−43- discussion 643−4.
197. Schmeisser A., Graffy C., Daniel W., et al. Phenotipic overlap between monocytes and vascular endothelial cells. Adv Exp Med Biol 2003- 522: 59−74.
198. Schofield P.M., Sharpies L.D., Caine N., et al. Transmyocardial laser revascularization in patients with refractory angina: arandomized controlled trial. Lancet, 1999, 353: 519−524.
199. Scholz D., Ziegelhoeffer Т., Helisch A., et al. Contribution ofarteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol 2002- 34: 775−87.
200. Schumacher В., Pecher P., von Specht В., et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circ. 1998- 97: 645−50.
201. Schunke M., Kruss С, Mecke H., Werner J.A. Characteristic features of wound healing in laser-induced incisions. Adv
202. Otorhinolaryngol. 1995 -49 :8−14
203. Selke FW, Ruel M. Vascular Growth Factor and Angiogenesis in Cardiac
204. Surgery. Ann Thorac Surg 2003- 75: S685−90.
205. Sellke F., Laham R., Edelman E., et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998- 65: 1540−4.
206. Sellke F., Simons M. Angiogenesis in cardiovascular disease: current status and therapeutic potential. Drugs 1999- 58(3): 391−6.
207. Sellke F.W., Ruel M. Vascular growth factors and angiogenesis in cardiac surgery. Ann Thorac Surg 2003- 75: S685−90.
208. Semenza, G. L. HIF-1 and human disease: One highly involved factor. Genes Dev. 2000- 14:1983−1991.
209. Semenza, G. L. HIF-l: Mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 2000- 88: 1474−1480.
210. Semenza, G. L. Hypoxia-inducible factor 1: Master regulator of 02 homeostasis. Curr. Opin. Genet. Dev. 1998- 8: 588−594.
211. Semenza, G. L. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol. 2002- 64: 993−998.
212. Shou M., Thirumutri v., Rajanogagam S et ol. Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels. J. Amer. Coll. Cardiol.- 1997. Vol. 29:1102−1106.
213. Shumacher В., Pecher P von Specht B.-U., Stregman T. Induction of neo-angiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary disease. Circulation, 1998, 97,7 645−650
214. Shumacher В., von Specht B.-U., Heberstroh J., Pecher P. The stimulation of neo-angiogenesis in the ischemic heart by the human growth factors FGF. J. Cardiovasc. Surg., 1998, 39: 445−453.
215. Shyu KG, Chang H, Isner JM. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci 2003−73: 563−79.
216. Simons M. Angiogenesis therapies for coronary artery disease. Ch.20 In Cardiac Drug Development Guide. Ed. By: M.K. Pugsley, Humana Press Inc., Totowa, NJ 2002.
217. Simons M., Post M. Angiogenesis. In: Topol EJ, editor. Textbook of interventional cardiology. Philadelphia: saunders- 2003, p.757−759.
218. Simons M., Ware A. Therapeutic angiogenesis in cardiovascular disease. Nature Reviews| Drug Discovery 2003-V.2: 863−871.
219. Simons, M. Therapeutic coronary angiogenesis: A fronte praecipitium a tergo lupi? Am. J. Physiol. 2001- 280: H1923-H1927.
220. Simons, M., Laham, R. J., Post, M. J., and Selike, F. W. Therapeutic angiogenesis: Potential role of basic FGP in patients with severe ischemic heart disease. BioDrugs 2000- 14: 13−20.
221. Solowiej A., Biswas P., Graesser D., et al. Lack of platelet endothelial cell adhesion molecule-1 attenuates foreign body inflammation because of decreased angiogenesis. Am Jpathol 2003- 162: 953−62.
222. Sommer A., Brewer M., Thompson R., et al. Human basic fibroblast growth factors: nucleotide gequence, genomic organization and expression in mammalian cells. J Cold Spring. Harb. Qant. Biol. 1986- 51 (partl):657−668.
223. Spertus J, Jones PG, Coen M, et al. transmyocardial C02 laser revascularization improves symptoms, function, and quality of life: 12-month results from a randomized controlled trial. Am J Med2001 -111:3418.
224. Springer M., Chen A., Kraft P., et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Moll Cell 1998−2:549−58.
225. Stamou SC, Boyce SW, Cooke RH, Carlos BD, Sweet LC, Corso PJ One year outcome after combined coronary artery bypass grafting and transmyocardial laser revasculanzation forrefractory angina pectoris. Am J Cardiol 2002,89: 1365−8
226. Stoica S.C., Sharpies L.D., Ahmed I. et al. And intraoperative events in cardiac Surgery. Eur. J.CardioThorac. Surg., 2002,21:41−46
227. Sullivan G., Sarembock I., Linden J. The role of inflammation in vascular diseases. J Leukoc Biol 2000- 67: 591−602.
228. Symes J., Losordo d., Vale P., et al. gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999- 68: 830−6 discussion, 836−7.
229. Tabata H, Silver M, Isner JM. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo-, critical role of secretion signal in use of naked DNA. Cardiovasc Res 1997−35:470−9. Erratum in Cardiovasc Res 1998−38:272.
230. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994−93:662−70
231. Taniyama Y., Morishita R., Hiraoka K., et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001- 104: 2344−50.
232. Thurston G., Suri C., Smith K., et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999- 286: 2511−4.
233. Tjomsland O, Aaberge L, Almdahl S, et al. Perioperative cardiac function and predictors for adverse events after transmyocardilal laser treatment Ann Thorac Surg 2000,69: 1098−103
234. Tjomsland O., Grand F., Kanellopoulos G.H. et al. Transmyocardial laser induces coronary hyperemia and reduces ischemia related arrhythmias J.Cardivasc. Surg., 1999,40, 3:325−331
235. Tomita N., Morishita R., Taniyama Y., et al. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003- 107: 1411−7.
236. Trehan N. Clinical experience with TMLR sole application and TMR combined with CABGIn T. Krabatsch R. Hetzer Transmyicardial lazer Revascularization G.J.Muller, H-P
237. Berlien (eds)Advanceas in Lazer Medicine 17, 1998
238. Tse H., et al. Angiogenesis in ischaemic myocardium by intramyocardialautologous bone marrow mononuclear cell implantation. Lancet 2003 -3 61:4749.
239. Unger EF, Banai S, Shou M, Jaklitsch M, Hodge E, Correa R et al. A model to assess interventions to improve collateral blood flow: continuous administration of agents into the left coronary artery in dogs. Cardiovasc Res 1993−27:785−91.
240. Unger EF, Shou M, Sheffield CD, Hodge E, Jaye M, Epstein SE. Extracardiac to coronary anastomoses support regional left ventricular function in dogs. Am J Physiol 1993 -264:H1567−74.
241. Unger, E. P., Banai, S., Shou, M., Lazarous, D. P., Jaklitsch, M. Т., Scheinowitz, M., et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am. J. Physiol. 1994- 266: H1588-H1595.
242. Van Royen N, Piek JJ, Buschmann I, et al. Stimulation of arteriogenesis: a new concept for the treatment of arterialocclusive disease. Cardiovasc Res. 2001- 49: 543−553.
243. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang С et al.
244. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNAencoding an HIF-lalpha/VP16 hybrid transcription factor. Circulation 2000−102:2255−61.
245. Virmani R., Burke A., Farb A., Atkinson J. B. Cardiovascular Pathology. Major problem in pathology. Vol. 40, 2 ed., 2001., W. B. Saunders сотр., Philadelphia, P. 541.
246. Walterberger J., Modulation of growth factor action: implications for the treatment of cardiovascular diseases.
247. Circulation. 1997−96: 4083−4094
248. Ware, J. A. and Simons, M. Angiogenesis in ischemic heart disease. Nat.1. Med. 1997- 3, 158−164.
249. Weintraub W.S., Jones E.L. et al. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery usingsaphenous venous grafts. Am. J. Cardiol. 1994 -73:103−112
250. Wilting J., Christ В., Bokeloh M. A modified chorioallantoic membrane
251. CAM) assay for gualitative and guantitative study of growth factors Anat Embryol., 1991−183: 259−271.
252. Yamamoto N, Kohmoto T, Gu A, DeRosa C, Smith CR, Burkhoff D Angiogenesis is enhanced in ischemic canine myocardium by transmyocardial laser revascularization J Am
253. Coll Cardiol 1998,31: 1426−33
254. Yamamoto N, Kohmoto T, Roethy W, Gu A, De Rosa C, Rabbani LE,
255. Smith CR, Burkhoff D. Histologic evidence basic fibroblast growth factor enhances the angiogenic effects of transmyocardial laser revascularization. Basic Res Cardiol 2000−95(l):55−63.
256. Yamamoto N., Kohomoto Т., Gu A., De Rosa C., Smith C. R., Burkoff D. Angiogenesis is enhanced in ischemic canine myocardium by transmyocardial laser revascularization // JACC. 1998. — Vol.31, № 6. — P. 1426−1433.
257. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992−257:1401−3.
258. Yano OJ, Bielefeld MR, Jeevanandam V, et al Prevention of acute regional ischemia with endocardial laser channels Ann
259. Thorac Surg 1993,56 :46−53
260. Yee A., Rosengart T. Angiogenesis and gene therapy for the treatment ofcoronary artery disease Ch.16. Jn «Advanced therapy in cardiac. Surgary» Il-nd K.L.Franco and E.D. Verrier edc. В С Deaker Inc. London, 2003.
261. Yla-Herttuala, S., Martin, J. F. Cardiovascular gene therapy. Lancet 2000- 355,213−222.
262. Zhang Y., Li J., Partovian C., et al. Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo. Am J Physiol Heart Circ Physiol 2003- 284: H2078−2082. 1
263. Zlotnik A. Y., Ahmad R. M., Reul R. M. et al. Neovascularization occurs at the site of closed laser channels after transmyocardial laser revascularization. Surg. Forum., 1996, 47: 286−7.